Nucleic acid preparation compositions and methods

• US 9,580,741 B2
• Filed: 06/05/2014
• Issued: 02/28/2017
• Est. Priority Date: 04/03/2009
• Status: Active Grant

• Current Assignee: Sequenom Incorporated (Laboratory Corporation Of America Holdings)
• Original Assignee: Sequenom Incorporated (Laboratory Corporation Of America Holdings)
• Inventors: Wisniewski, Michele Elizabeth, Kwong, William Hang, Mohsenian, Firouz, Ding, Jian-Hua
• Primary Examiner(s): Martinell, James
• Application Number:
  US14/296,732
• Publication Number:
  US 20140349291A1
• Time in Patent Office: 999 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C12N 15/1003 Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
• CPC Class Codes: C12N 15/1006 by means of a solid support carrier, e.g. particles, polymers
• CPC Class Codes: C12Q 1/68 involving nucleic acids
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 2527/125 Specific component of sample, medium or buffer
• CPC Class Codes: C12Q 2565/137 Chromatographic separation
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided herein are methods and compositions to extract and enrich by, physical separation or amplification, relatively short nucleic acids from a nucleic acid composition containing a high background of longer nucleic acids (e.g., host or maternal nucleic acids; genomic nucleic acid and the like).

Claims

1. A method for detecting the presence or absence of fetal nucleic acid in a substantially cell-free biological composition, which comprises:

(a) contacting cell-free nucleic acid from the substantially cell-free biological composition with a solid phase under association conditions, wherein;

(i) the nucleic acid of the biological composition comprises relatively short nucleic acid and relatively long nucleic acid,

(ii) The relatively short nucleic acid may comprise fetal nucleic acid,

(iii) the relatively short nucleic acid is 300 base pairs or less,

(iv) the relatively long nucleic acid is larger than 300 base pairs, and

(v) the association conditions do not include polyethylene glycol;

whereby the relatively short nucleic acid and the relatively long nucleic acid are associated with the solid phase;

(b) introducing the solid phase after (a) to dissociation conditions that comprise a volume exclusion agent and a salt, wherein;

(i) the salt is not a chaotropic salt, and

(ii) the relatively short nucleic acid preferentially dissociates from the solid phase under the dissociation conditions as compared to the relatively long nucleic acid, thereby yielding dissociated nucleic acid;

(c) separating the dissociated nucleic acid from the solid phase, whereby the fetal nucleic acid, when present, is enriched in the dissociated nucleic acid relative to in the cell-free nucleic acid from the substantially cell-free biological composition, thereby yielding a sample comprising enriched fetal nucleic acid, when present; and

(d) detecting the presence or absence of fetal nucleic acid in the sample comprising enriched fetal nucleic acid, when present, thereby detecting the presence or absence of fetal nucleic acid in the substantially cell-free biological composition.

2. The method of claim 1, wherein the fetal nucleic acid comprises a fetal-specific nucleotide sequence.

3. The method of claim 2, wherein the fetal-specific nucleotide sequence is a Y-chromosome sequence.

4. The method of claim 2, wherein the fetal-specific nucleotide sequence is a mRNA sequence.

5. The method of claim 2, which further comprises detecting the presence or absence of a prenatal disorder, wherein the presence or absence of the fetal nucleic acid is indicative of the presence or absence, respectively, of the prenatal disorder.

6. The method of claim 5, wherein the prenatal disorder is a chromosome abnormality.

7. The method of claim 6, wherein the chromosome abnormality is a trisomy.

8. The method of claim 7, wherein the trisomy is trisomy 21, trisomy 18, trisomy 13 or a combination thereof.

9. The method of claim 1, which further comprises detecting the presence or absence of a prenatal disorder, wherein the presence or absence of the fetal nucleic acid is indicative of the presence or absence, respectively, of the prenatal disorder.

10. The method of claim 9, wherein the prenatal disorder is a chromosome abnormality.

11. The method of claim 10, wherein the chromosome abnormality is a trisomy.

12. The method of claim 11, wherein the trisomy is trisomy 21, trisomy 18, trisomy 13 or a combination thereof.